TY  - CONF

T1  - MO2 - MODELLING OVERALL SURVIVAL IN IMMUNOTHERAPY USING PARAMETRIC TECHNIQUES: AVELUMAB IN PREVIOUSLY TREATED METASTATIC MERKEL CELL CARCINOMA

JO  - Value in Health

PY  - 2018/10/01

AU  - Bullement A

AU  - Amin A

AU  - Stapelkamp C

AU  - Willis A

AU  - Lilley C

AU  - Hatswell AJ

AU  - Pescott C

AU  - Bharmal M

ED  - 

DO  - DOI: 10.1016/j.jval.2018.09.062

PB  - Elsevier BV

VL  - 21

SP  - S11

EP  - S11

Y2  - 2024/12/26

ER  -